the Image

Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Share this:
Brief Title Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer
Official Title A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Depo-Provera (Medroxyprogesterone Acetate) (NSC #26386) Compared to Depo-Provera Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus
Principal Investigator Brooks, Rebecca
Brief Summary This randomized phase II trial studies how well medroxyprogesterone acetate with or without entinostat before surgery works in treating patients with endometrioid endometrial cancer. Medroxyprogesterone acetate is a progesterone, a hormone produced by body normally. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Given medroxyprogesterone acetate with or without entinostat may work better in treating patients with endometrioid endometrial cancer.
Gender Female
Ages 18 Years
Enrollment 50
Accepts Healthy Volunteers No
Lead Sponsor National Cancer Institute (NCI)NIH
Collaborator
Study Design
Study Phase Phase 2
Study Type Interventional
Contact Name Saketh R. Guntupalli
Contact Phone 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
Condition Grade 1 Endometrial Endometrioid Adenocarcinoma
Detail for Health Professional (on clinicaltrials.gov)
More clinical trials by this PI